Bayer stock gains as Sunharbo wins first US Factor XIa approval
Published on 11/12/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSunharbo enters the US market
- The FDA cleared Bayer's first-in-class Factor XIa inhibitor for secondary stroke prevention.
- The Phase 3 OCEANIC-STROKE study enrolled 12,327 patients and showed a 26% reduction in ischemic stroke versus placebo.
- Bayer expects US shipments to begin in mid-to-late November, while European and Japanese reviews continue.
Bayer's SUNHARBO has cleared a major regulatory hurdle in the United States, opening a new commercial opportunity in cardiovascular medicine. The U.S. Food and Drug Administration approved the 50-milligram asundexian tablet on November 9 for adults with a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, used in combination with antiplatelet therapy.
Bayer announced the approval in a release dated November 10. The company said SUNHARBO is the first Factor XIa inhibitor approved in the United States and described the once-daily medicine as a new approach to secondary stroke prevention. The Bayer release said shipments should begin in mid-to-late November, with hospitals and pharmacies expected to be able to order the medicine shortly afterward.
Trial results support approval
The approval rests on the Phase 3 OCEANIC-STROKE study, which randomized 12,327 patients to SUNHARBO or placebo while both groups received antiplatelet therapy. Bayer reported that ischemic stroke occurred in 6.2% of patients taking SUNHARBO compared with 8.4% in the placebo group. That represented a 26% reduction, with a hazard ratio of 0.74 and a P value below 0.0001.
The safety profile remains relevant for investors assessing the drug's commercial potential. Major bleeding rates were similar at 1.6 and 1.5 events per 100 person-years for SUNHARBO and placebo, respectively. Gastrointestinal bleeding was more frequent with SUNHARBO, at 2.7 versus 2.1 events per 100 patient-years, while diarrhea was the most frequently reported adverse reaction above 3%.
Launch execution is next
Regulatory clearance removes a key development risk, but revenue will depend on prescribing decisions, payer access and the speed of the US rollout. Bayer's first commercial focus will be secondary prevention after qualifying strokes or high-risk TIAs; the FDA indication does not cover stroke prevention in atrial fibrillation.
Sunharbo had already received approval in China on October 26. Bayer said applications remain under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare. Further approvals could broaden the addressable market, but the timing and scope of those decisions remain ahead.
Bayer stock traded at 57.66 euros on Lang & Schwarz at 11:07 CET on Thursday, November 12, 1.59 percent above the Xetra close of Wednesday, November 11. The move places the shares above the prior Xetra session as investors assess the drug's transition from clinical program to commercial product.
Bayer stock at a glance
- Company: Bayer Aktiengesellschaft
- ISIN: DE000BAY0017
- Ticker: BAYN.DE
- Lang & Schwarz price: 57.66 euros at 11:07 CET on November 12, 2026
- Change versus prior Xetra close: 1.59 percent
- Xetra comparison: 56.76 euros on November 11, 2026
European healthcare shares remain sensitive to regulatory decisions, trial readouts and drug-pricing expectations; investors can follow the DAX market environment.
More news and analyses are available on More news and analyses on Bayer stock.
